Zhitong Finance App News, Sinopharm Hyundai (600420.SH) issued an announcement. Recently, Sinopharm Group Industry Co., Ltd. (Sinopharm Industry for short), a wholly-owned subsidiary of the company, received the “Drug Registration Certificate” for pentamethylene hydrochloride injection (1ml: 0.5mg) approved and issued by the State Drug Administration. This drug is a selective anticholinergic drug. The main indications are: it is used for administration before anesthesia to inhibit salivary and airway gland secretion; it is used for emergency treatment of organophosphorus toxicants (pesticides) poisoning and maintenance of atropinization in the late stages of poisoning or after cholinesterase (ChE) aging.

According to reports, Sinopharm has obtained a drug registration certificate for pentamethylene glycol injection (1ml: 1mg) in September 2025 and passed the consistency evaluation. The new specifications and passing the consistency evaluation will further enrich the company's product range, help further enhance the company's comprehensive market competitiveness in related pharmaceutical fields, and have a positive impact on the company's future development.

Disclaimer:Webull uses external vendor Google Translation Service for news translations where we endeavour to ensure these are correct, however, we recommend that you please double-check this information accordingly. Webull is not responsible for translation errors or issues.